On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of ailse scamhóg conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes meall cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanoma (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Nocht Squibb go bhfuil an chuideachta tar éis iarratas Opdivo le haghaidh cóireáil tásca ailse scamhóg a chur faoi bhráid an FDA agus riarachán cógaisíochta an AE. Ar ndóigh, ní hamháin go mbeidh an Chuideachta Squibb uaillmhianach sásta ach le hailse scamhóg agus melanóma. Go deimhin, tá Squibb ag déanamh níos mó ná 35 staidéar ar Opdivo ina n-aonar nó i gcomhcheangal le drugaí eile chun cineálacha éagsúla meall a chóireáil. De réir anailísithe, sroichfidh díolacháin todhchaí Opdivo chomh hard le 5 billiún dollar SAM.
The cancer immunotherapy research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
Tuairisc mhionsonraithe Bhéarla:
Scóráil an druga imdhíon-o ncology standout Bristol-Myers Squibb ($ BMY), a ceadaíodh an mhí seo caite mar Opdivo, rath thar na bearta i dtriail ailse scamhóige déanacha, rud a chuir leis na hionchais díolacháin don chóireáil piosaiochta.
I staidéar le 272 othar a chuir Opdivo in aghaidh an doicteacs caighdeánach um marú ailse, léirigh taispeántas drugaí Bristol-Myers marthanacht iomlán níos fearr i gcomparáid leis an ngéag rialaithe gur shroich sé a phríomhphointe deiridh roimh an sceideal, agus é i gceannas ar choiste monatóireachta sonraí na trialach. deireadh a chur leis an staidéar go luath. Tá cuireadh anois ag Bristol-Myers d’othair sa ghrúpa docetaxel rogha an diúltaithe i Opdivo trí staidéar síneadh lipéad oscailte.
Tá cóireáil Bristol-Myers deartha chun ionsaí chóras imdhíonachta ar siadaí a ghalbhánú trí chonair ar a dtugtar PD-1 a bhlocáil, rud a fhágann nach bhfuil seiceáil déanta air, a ligeann do chealla ailse pas a fháil faoi deara ag cosaintí nádúrtha an chomhlachta. Cosúil le Keytruda cosúil le Merck ($ MRK), bhuaigh Opdivo faomhadh FDA anuraidh mar chóireáil le haghaidh melanoma, ach seasann druga Bristol-Myers ina aonar in ailse scamhóg, mar is é an rath cliniciúil is déanaí ná an chéad uair a chláraigh coscaire PD-1 a buntáiste marthanais i gcoinne an ghalair , dúirt an chuideachta .
Opdivo’s particular promise in ailse scamhóg cille neamh-bheag has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
Tá iarratais ailse scamhóg curtha isteach ag Bristol-Myers sna Stáit Aontaithe agus san Eoraip le haghaidh Opdivo in ailse scamhóg, ag súil le húsáid an druga a leathnú níos déanaí i mbliana.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, ailse ceann agus muineál, glioblastoma, Non-Hodgkin lymphoma and other cancers.
